The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.
|Slideshows|December 26, 2017
Statins and Risk of Parkinson Disease
Author(s)Veronica Hackethal, MD
There has been long-running controversy regarding the association between statins and PD risk. Two studies with conflicting results are examined here.
Advertisement
Advertisement
Related to this article
Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.
The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Sevasemten Misses Primary Endpoint in Pivotal Trial for Becker Muscular Dystrophy
2
QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS
3
Final Results Reported for EPISOD1 Trial of SOD1-ALS Gene Therapy AMT-162
4
Analyzing Inebilizumab’s Durable Benefit in MINT Open-Label Extension
5